Sacramento, CA -- March 13, 2018 -- InvestorsHub NewsWire -- A
new report has been published on Innovest Global, Inc. (OTC Pink:
IVST). Innovest Global, Inc. is a diversified holding company that
focuses on acquiring niche, high-growth businesses that are capable
of generating significant annual revenue. The company’s planned
subsidiaries operate across biotechnology & health sciences,
commercial & industrial energy and distribution, auto sales, a
national call center, and more.
The report provides an overview of biotechnology’s past
performance, outlook, developments, industry trends, industry
equity research reports, and Innovest’s recently announced move to
form a biotech and health sciences division.
Morningstar: Biotech Positioned to Return to Long-Term
Market Outperformance
The health sector has been one of the top performers over the
past many decades. In fact, the health sector has been generating
an annualized rate of return of 11% since 1963. Only consumer
staples managed to have greater return figures during the same time
period.
Morningstar analysts note that the biotech industry has
seen three major cycles thus far: first cycle came in late 1990s,
second in mid-2000s, and latest cycle took place between 2012 and
2016.
The analysts note that a perfect storm of bearish activity began
to overtake biotech in early 2015, which has led to a period of
underperformance. Exacerbated valuations, ending drug cycles, and a
tumultuous U.S. presidential election helped push biotech stocks
down the past couple of years.
However, research analysts and fund managers are increasingly
interested in the growing resurgence within the industry. Among the
key factors driving the rebound are development of revolutionary
new drugs, the aging American population, and slashing
regulatory hurdles at the U.S. Food and Drug Administration
(FDA).
Dale Chan, manager of Prudential Jennison Health Sciences mutual
fund, says he sees innovation "across all kinds of interesting
areas," including in oncology-related gene therapies and around
depression, muscular sclerosis, and epilepsy treatments.
However, Mr. Chan notes that he sees a vast majority of the
biotech innovation being accomplished by small- and mid-cap stocks.
While larger stocks will serve as better valuation-based
opportunities, according to the fund manager. Mr. Chan notes that
“the outlook of the small and mid-cap names is as exciting as it’s
ever been,” as drug cycles and patent cliffs draw near for larger
biotech companies.
According to Grand View Research, Inc., the global
biotechnology market is forecast to hit $727.10 billion by 2025.
The market research firm notes that most of the growth will most
likely be generated by regenerative medicines and genetics in
diagnostics
Innovest Global Launching New Biotech and Health
Sciences Division This Spring
Innovest Global, Inc. recently announced that it is preparing to
launch a new biotechnology and health sciences division this
spring, which will be headquartered in Los Angeles, CA. The
new division will be led by world-renowned
neuroscientist, Dr. Dwain Morris-Irvin.
Dr. Morris-Irvin received his PhD from the UCLA School of
Medicine and Masters in Public Health from UCLA School of Public
Health. Furthermore, the distinguished neuroscientist trained at
The Wallenberg Neuroscience Center at Lund University in Lund,
Sweden.
Furthermore, Dr. Dwain Morris-Irvin is an expert in patent
generation of therapies and treatments related to Parkinson’s,
brain cancer, and more.
“Dr. Morris-Irvin is an active participant in many Biotechnology
and Health Science endeavors, and is an expert including patent
generation in such areas as treatments for Parkinson’s, brain
cancer, and even cosmetic application of advanced bioscience,” said
Dan Martin, CEO of Innovest Global.
The official Twitter page of Innovest Global, Inc. has
recently announced a variety of major meetings with potential
acquisition targets, business owners, and local congressional
representatives. The U.S. Congressman in Innovest’s district in
Ohio, Dave Joyce, has recently met with Dan Martin and the Innovest
Global team a couple of times over the past month.
Innovest announced that it has generated revenues of
$388,000, through half of the first quarter 2018. This beat
management’s estimates by 55% and puts the company well on its way
to beating its goal of reporting $500,000 in revenue per
quarter.
Innovest is continuing to vet PCAOB auditors to be
engaged with the company and assist with auditing the financials.
This is in addition to the fact that the company’s corporate
counsel is an official OTCQX sponsor, which positions the company
to continue pursuing uplisting endeavors that have been laid out in
previous press releases.
For more information on Innovest Global, Inc., please
visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/03/12/how-to-play-the-resurgence-in-biotechnology/
SpotlightGrowth.com is a digital hub for micro-caps,
small-caps, crowdfunding, cryptocurrency, and other emerging growth
investors. SpotlightGrowth.com serves as our media
subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third
party, to provide investor relations services for its
clients. Spotlight Growth creates exposure for companies
through a customized marketing strategy, including design of
promotional material, the drafting and editing of press releases
and media placement.
All information on featured companies is provided by the
companies profiled, or is available from public sources. Spotlight
Growth and its employees are not a Registered Investment Advisor,
Broker Dealer or a member of any association for other research
providers in any jurisdiction whatsoever and we are not qualified
to give financial advice. The information contained herein is based
on external sources that Spotlight Growth believes to be reliable,
but its accuracy is not guaranteed. Spotlight Growth may
create reports and content that has been compensated by a company
or third-parties, or for purposes of self-marketing. Spotlight
Growth was compensated two thousand eight hundred dollars cash and
fifty thousand restricted shares for the creation and dissemination
of this content.
This material does not represent an investment solicitation.
Certain statements contained herein constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may include, without
limitation, statements with respect to the Company’s plans and
objectives, projections, expectations and intentions. These
forward-looking statements are based on current expectations,
estimates and projections about the Company’s industry,
management’s beliefs and certain assumptions made by
management.
The above communication, the attachments and external Internet
links provided are intended for informational purposes only and are
not to be interpreted by the recipient as a solicitation to
participate in securities offerings. Investments referenced
may not be suitable for all investors and may not be permissible in
certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and
employees may have bought or sold or may buy or sell shares in the
companies discussed herein, which may be acquired prior, during or
after the publication of these marketing materials. Spotlight
Growth, its affiliates, officers, directors, and employees may sell
the stock of said companies at any time and may profit in the event
those shares rise in value. For more information on our
disclosures, please
visit: http://spotlightgrowth.com/index.php/disclosures/
Matt Rego 9165257147 mrego@spotlightgrowth.com